C
Cenyx Biotech
Nanozyme therapeutics for acute inflammatory diseases
About Cenyx Biotech
Cenyx Biotech is a South Korean nanomedicine company founded in 2016 by Professor Seung-Hoon Lee, a neurologist at Seoul National University Hospital (SNUH). The company was established to commercialize a decade's worth of research into nanozymes, which are nanomaterials with enzyme-like characteristics. Professor Lee, who serves as CEO, is a recognized expert in stroke and inorganic nanoparticles, with his research on the effects of cerium oxide nanoparticles on subarachnoid hemorrhage models winning an award from the American Stroke Association in 2018.
The company's core technology is its proprietary InnoSurface® platform, which develops nanozymes designed to scavenge excess free radicals, thereby treating severe acute inflammatory conditions. Its lead candidate, CX213, is a first-in-class, cerium oxide-based nanozyme targeting subarachnoid hemorrhage (SAH), a life-threatening brain bleed with no currently approved emergency treatments. In late 2024, Cenyx received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials for CX213 in the second quarter of 2025. The drug has also received orphan drug designation from the FDA. The company's pipeline also includes CX301, a treatment for acute kidney injury, which is expected to advance toward IND approval in 2025.
Cenyx Biotech's business model is focused on developing its pipeline assets through clinical trials and seeking strategic partnerships for global commercialization. The company operates a research center and is establishing a GMP-compliant manufacturing facility in Seoul. Cenyx has successfully raised capital, including a Series A round of KRW 18.5 billion (approx. $16.5M) in 2021 from investors including SBI Investment Korea, InterValue Partners, and Partners Investment, to fund its clinical trials.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 53.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Neurology, Critical medical care, Inflammatory Diseases
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2026 | $10M | $75M | Aju IB Investment · CKD Venture Capital Corporation · SL Investment · Partners Investment | ↗ |
| SERIES A✓Equity / VC | Apr 2021 | $16M | $62M | Aju IB Investment · Daekyo · CKD Venture Capital Corporation · WONIK Investment Partners | — |
Growth signals
Latest recorded traffic for Cenyx Biotech is 270 monthly website visits, down 86.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
KeystoneBioBiotherapeutics targeting P. gingivalis for systemic inflammation. |
— | Operational | — | — | — |
Noetica PharmaPatented small molecules for pediatric orphan neuroprotection. |
Boulogne-Billancourt, France | Operational | |||
Zermatt BiotechAI-optimized STING inhibitors for neuroinflammatory diseases. |
— | Operational | |||
| Paris, France | Operational | ||||
Neoflow TechnologiesPrecise Vasospasm Electrotherapy |
Haifa, Israel | Operational | |||
NanoNewronBiologics delivery across the blood-brain barrier for CNS diseases |
Union, United States | Operational | |||
ShearitDisruptive injectable polymer for acute stroke treatment |
Albuquerque, United States | Operational | |||
| Abingdon, United Kingdom | Low Activity |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cenyx Biotech in the Seoul ecosystem
The Cenyx Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Aju IB Investment- CCCKD Venture Capital Corporation
- DIDaekyo Investment
WONIK Investment Partners
Series A6 investors entered at this stage
Daekyo
SL Investment
Partners Investment
InterValue Partners
Scale Up Partners
SBI Investment
Other known investors1 additional known investor
SBI Investment Korea
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cenyx Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cenyx Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








